PUBLIC COMPANY
save$CRNXCrinetics Pharmaceuticals, Inc.
$CRNX84.690.00%San Diego, CA, USupdated 6h ago
Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.
community read0 votes
pipeline
4
marketed
1
phase 3
1
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(4)
pipeline depth4 products
1Phase 21Phase 31Marketed1Unknown
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase2A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
- phase3A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
- phase3A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly
- phase3A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)
- phase2A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)
- phase3A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
- phase2Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
- phase1A Study to Assess Pharmacokinetics, Safety, and Tolerability of Atumelnant in Healthy Japanese and Caucasian Participants
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 8, 26SELLKnight Jeff E.· Chief Dev. & Operating Officer−$3.42M↗
- Mar 16, 26SELLStruthers Richard Scott· President & CEO−$490K↗
- Mar 16, 26SELLStruthers Richard Scott· President & CEO−$332K↗
- Mar 16, 26SELLBetz Stephen F.· Chief Scientific Officer−$236K↗
- Mar 16, 26SELLKnight Jeff E.· Chief Operating Officer−$221K↗
- Mar 16, 26SELLBetz Stephen F.· Chief Scientific Officer−$160K↗
- Mar 16, 26SELLKnight Jeff E.· Chief Operating Officer−$150K↗
- Mar 12, 26SELLVivaldi Coelho Rogerio· director−$162K↗
- Mar 12, 26SELLVivaldi Coelho Rogerio· director−$19K↗
- Mar 3, 26SELLSchilke Tobin· Chief Financial Officer−$266K↗
- Mar 3, 26SELLOkey Stephanie· director−$119K↗
routine RSU / option mechanics (6)
- Apr 8, 26option exerciseKnight Jeff E. · Chief Dev. & Operating Officer49,474 sh
- Apr 8, 26option exerciseKnight Jeff E. · Chief Dev. & Operating Officer19,336 sh
- Apr 8, 26option exerciseKnight Jeff E. · Chief Dev. & Operating Officer9,624 sh
- Apr 8, 26option exerciseKnight Jeff E. · Chief Dev. & Operating Officer49,474 sh
- Apr 8, 26option exerciseKnight Jeff E. · Chief Dev. & Operating Officer9,624 sh
- Apr 8, 26option exerciseKnight Jeff E. · Chief Dev. & Operating Officer19,336 sh
🐶 Hiring Signal
News
- Vertex was sole bidder in high-premium Crinetics acquisitionAnalysts expect new details on the lead-up to the deal “are likely to reignite” investor scrutiny that Vertex overpaid in what’s poised to be its largest-ever transaction.biopharma_dive · 29d ago
- Vertex was only bidder for Crinetics in year's second-highest M&A premiumTo gain control of Crinetics Pharmaceuticals, Vertex Pharmaceuticals was willing to pay the second-highest premium so far in biopharma's banner year for M&A. And the Boston drugmaker was bidding ag…endpoints · 29d ago
- STAT+: Compass says depression drug has long-lasting benefitsVertex makes its largest-ever deal, skyrocketing health insurance costs, and more biotech news from The Readoutstat · 1mo ago
- Vertex to acquire Crinetics in $10B foray into endocrine disease drugsVertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it paid stirred debate among analysts and investors.biopharma_dive · 1mo ago
Data sources
last refreshed 17m ago
Found something off?
comments(0)
5-min edit window · permanent after that